Cell and Gene Therapy Today—May 28, 2026

This week’s Gene and Cell Therapy update highlights regulatory progress, gene editing advances, CAR T research momentum, and expanding platform partnerships across rare disease, oncology, cardiovascular, and autoimmune programs.

In Today’s Newsletter

Dive deeper

💊 Otarmeni EMA filing accepted [1] [EU • 22 May 2026]

https://investor.regeneron.com/news-releases/news-release-details/otarmenitm-lunsotogene-parvec-receives-ema-filing-acceptance
Context: Otarmeni (Regeneron; lunsotogene parvec) is an in vivo AAV gene therapy for biallelic OTOF variant-associated hearing loss.
Key point: EMA accepted the MAA under Accelerated Assessment, supported by CHORD data in 24 participants.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Rznomics secures WHO INN for RZ-001 [2] [Korea • 27 May 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31793
Context: Taspitimagene advec (Rznomics; RZ-001) is an RNA-based anticancer gene therapy using a trans-splicing ribozyme platform.
Key point: WHO assigned the INN “Taspitimagene advec,” with proposed listing expected in WHO Drug Information List 136.
Implication: Signals pipeline investment and modality expansion.

🎯 Genethon and Ampersand partner on tissue-specific AAVs [3] [France • US • 21 May 2026]

https://www.prnewswire.com/news-releases/genethon-and-ampersand-biomedicines-announce-partnership-to-design-novel-aav-vectors-with-enhanced-tissue-specificity-for-more-effective-and-better-tolerated-gene-therapies-302777923.html
Context: Genethon and Ampersand Biomedicines will engineer AAV capsids with improved tissue specificity.
Key point: The collaboration will use Ampersand’s AND platform and Genethon’s AAV expertise, initially focusing on skeletal muscle.
Implication: Signals pipeline investment and modality expansion.

❤️ Lilly advances VERVE-102 after LDL-C reduction data [4] [US • 25 May 2026]

https://www.fiercebiotech.com/biotech/lilly-preps-ph-2-launch-after-verve-gene-editor-cuts-cholesterol-par-pcsk9-inhibitors
Context: VERVE-102 (Lilly/Verve; one-time PCSK9 base editor) is being studied in Phase 1b Heart-2.
Key point: Fierce reported 62% LDL-C reduction at the highest dose, sustained up to 18 months in the analysis described.
Implication: May influence prescriber choice and payer reviews pending full data.

🛡️ A2 Bio reports EVEREST-2 CAR T update [5] [US • 21 May 2026]

https://www.businesswire.com/news/home/20260515085966/en/A2-Biotherapeutics-Presents-Safety-and-Efficacy-Data-from-the-EVEREST-2-Clinical-Study-Including-Update-on-the-First-Complete-Response-to-CAR-T-Cell-Therapy-in-a-Patient-with-Non-Small-Cell-Lung-Cancer
Context: A2B694 (A2 Biotherapeutics; logic-gated MSLN-targeted Tmod CAR T) is being studied in EVEREST-2.
Key point: Company reported updated data including a complete response in one NSCLC patient, with no new safety signals noted.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 LRA and Genentech fund lupus CAR T research [6] [US • 26 May 2026]

https://www.prnewswire.com/news-releases/lupus-research-alliance-and-genentech-fund-researchers-translating-car-t-success-into-durable-lupus-treatments-302780420.html
Context: Lupus Research Alliance and Genentech launched awards for immune-resetting therapies in lupus.
Key point: Three projects will study how CD19 CAR T may reset immunity, affect remission durability, and inform future lupus treatments.
Implication: Signals pipeline investment and modality expansion.

🫀 BioCardia reports CardiAMP CMI open-label data [7] [France • 21 May 2026]

https://www.manilatimes.net/2026/05/21/tmt-newswire/globenewswire/biocardia-announces-cardiamp-chronic-myocardial-ischemia-trial-results-presented-at-europcr-showed-durable-improvements-in-exercise-tolerance-with-reduced-angina-frequency/2349156
Context: CardiAMP Cell Therapy (BioCardia) was evaluated in a preliminary open-label cohort for chronic myocardial ischemia.
Key point: Company reported improved exercise tolerance and reduced angina frequency through follow-up in refractory angina patients.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧠 TreeFrog presents TFG-001 Parkinson’s preclinical data [8] [France • 25 May 2026]

https://www.businesswire.com/news/home/20260524006397/en/TFG-001-A-Novel-3D-Neural-Microtissue-Cell-Therapy-Demonstrates-Superior-Functionality-and-Reinnervation-for-Parkinsons-Disease
Context: TFG-001 (TreeFrog Therapeutics) is a 3D neural microtissue cell therapy for Parkinson’s disease.
Key point: Company reported preclinical dopamine release, graft-derived reinnervation, and motor recovery signals across translational models.
Implication: Signals pipeline investment and modality expansion.

Why It Matters

Regulatory momentum is building for rare-disease gene therapy, with Otarmeni moving through EMA review after US approval.
Gene editing for cardiovascular disease is nearing larger clinical testing, led here by Lilly’s VERVE-102 Phase 2 planning.
Solid-tumor CAR T remains early, but A2 Bio’s NSCLC case keeps logic-gated approaches in focus.
Autoimmune CAR T research is shifting from early clinical promise toward mechanisms of durable immune reset.
Manufacturing and targeting remain central themes, from AAV capsid specificity to scalable 3D cell therapy platforms.

📚 See the full Cell and Gene Therapy archive on our research hub page.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Cell and Gene Therapy news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is Otarmeni from Regeneron?

Otarmeni (lunsotogene parvec) is an in vivo AAV gene therapy for biallelic OTOF variant-associated hearing loss. EMA accepted its MAA under Accelerated Assessment. [1]

What changed for Rznomics’ RZ-001?

WHO assigned the INN “Taspitimagene advec” to RZ-001, moving the program from an internal code toward an internationally recognized naming system. [2]

What are Genethon and Ampersand trying to improve?

They aim to design AAV capsids with better tissue specificity, initially for skeletal muscle, to improve targeting and potentially reduce systemic exposure. [3]

What is VERVE-102?

VERVE-102 is a one-time PCSK9 base editor from Verve, now part of Lilly. The reported Phase 1b data support Phase 2 planning. [4]

Why is A2B694 notable in EVEREST-2?

A2 Bio reported an updated complete response in one NSCLC patient treated with its logic-gated MSLN-targeted Tmod CAR T. This remains early clinical evidence. [5]

What are LRA and Genentech funding in lupus?

They are funding studies of CD19 CAR T immune resetting, including remission durability, relapse biology, and immune tolerance mechanisms. [6]

Entities / Keywords

Regeneron, Otarmeni, lunsotogene parvec, DB-OTO, OTOF-related hearing loss, CHORD, EMA, MAA
Rznomics, RZ-001, Taspitimagene advec, RNA-based gene therapy, trans-splicing ribozyme, glioblastoma, hepatocellular carcinoma
Genethon, Ampersand Biomedicines, AAV capsids, AND Platform, tissue-specific ligands, skeletal muscle
Eli Lilly, Verve Therapeutics, VERVE-102, PCSK9, base editing, LDL-C, Heart-2, HeFH, CAD
A2 Biotherapeutics, A2B694, A2B543, EVEREST-2, Tmod CAR T, MSLN, NSCLC, HLA-A*02 LOH
Lupus Research Alliance, Genentech, CD19 CAR T, lupus, immune resetting, remission durability
BioCardia, CardiAMP Cell Therapy, chronic myocardial ischemia, refractory angina, EuroPCR
TreeFrog Therapeutics, TFG-001, Parkinson’s disease, 3D neural microtissue, C-Stem